BPA for tryvio
Active Awarded Last action
- Contract number
- 36E79725A0005
- Awardee
-
Idorsia Pharmaceuticals US Inc. UEI YWKKJS5RYQJ9
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 84% complete
- IDV ceiling
- $3,100,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement (BPA), awarded on February 19, 2025, by the Department of Veterans Affairs (VA) National Acquisition Center to Idorsia Pharmaceuticals US Inc., establishes an indefinite delivery vehicle for the procurement of TRYVIO (orexin inhibitors) and related sleep-regulating pharmaceuticals. The contract represents a single award with no set-aside provisions and carries a ceiling value of $3,100,000.00, with an ultimate completion date of February 18, 2027. The award constitutes an exercise of Option Year 1 under the original BPA (36E79725A0005), indicating continuation of an existing supply relationship for specialized pharmaceutical products integrated into the VA's Pharmaceutical Prime Vendor Program, which serves veteran populations across the healthcare system.
Under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), this BPA ensures reliable availability of orexin inhibitors—a class of medications used for sleep disorder management—to eligible veteran patients through established VA procurement channels. Idorsia Pharmaceuticals US Inc., a foreign-owned pharmaceutical manufacturer registered in the System for Award Management since February 2022, serves as the prime contractor responsible for maintaining product supply throughout the contract period. The indefinite delivery structure allows the VA to place task orders as needed, enabling efficient procurement of critical sleep-regulating medications while maintaining budget control through the established ceiling value, thereby supporting the VA's objective of ensuring continuous pharmaceutical availability across its integrated service networks.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0005?
36E79725A0005 was awarded to Idorsia Pharmaceuticals US Inc. by National Acquisition Center (Headquarters) on February 19, 2025.
How much is contract 36E79725A0005 worth?
36E79725A0005's own ceiling is $3,100,000.
Who can order from contract 36E79725A0005?
36E79725A0005 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0005 under another contract?
Yes. 36E79725A0005 is a blanket purchase agreement under 36F79722D0224, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0005 competed?
The extent of competition for 36E79725A0005 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV